Table 3. Frequency of EGFR mutations in DNA from the pleural effusion fluid of NSCLC patients according to (A) gender, (B) histology, (C) smoking habit, and (D) response to gefitinib.
| (A) Gender and EGFR mutation status | |||
|---|---|---|---|
|
EGFR mutation
|
|||
| + | – | ||
| Female | 7 | 14 | |
| Male | 4 | 18 | P=0.310 |
| (B) Histology and EGFR mutation status | |||
|
EGFR mutation
|
|||
| + | − | ||
| Ad | 11 | 28 | |
| Non-Ad | 0 | 4 | P=0.558 |
| (C) Smoking habit and EGFR mutation status | |||
|
EGFR mutation
|
|||
| + | − | ||
| Never | 7 | 11 | |
| Current/former | 4 | 21 | P=0.156 |
Ad=adenocarcinoma; EGFR=epidermal growth factor receptor; +=mutation-positive; −=no mutations.
(A)(B)(C); a total of 43 samples were evaluated.